Online citations, reference lists, and bibliographies.
← Back to Search

A Mutation In The Promoter Of The Lipoprotein Lipase (LPL) Gene In A Patient With Familial Combined Hyperlipidemia And Low LPL Activity.

W. Yang, D. Nevin, R. Peng, J. Brunzell, S. Deeb
Published 1995 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
We have identified a naturally occurring mutation in the promoter of the lipoprotein lipase (LPL) gene. One of 20 patients with familial combined hyperlipidemia (FCHL) and reduced levels of postheparin plasma LPL activity was found to be a heterozygote carrier of this mutation. The mutation, a T-->C substitution at nt -39, occurred in the binding site of the transcription factor Oct-1. As a result, the transcriptional activity of the mutant promoter was < 15% of wild type, as determined by transfection studies in the human macrophage-like cell line THP-1. This decrease in promoter activity was observed in undifferentiated as well as in phorbol ester-differentiated THP-1 cells. Furthermore, the inductive effect of elevating the levels of intracellular cAMP was equally reduced. This mutation was not present among 20 FCHL patients with normal plasma LPL levels nor has it been reported among individuals with familial LPL deficiency. Thus, heterozygosity for LPL promoter mutations may be one of several factors that contribute to the etiology of FCHL.

This paper is referenced by
Defects of insulin action on fatty acid and carbohydrate metabolism in familial combined hyperlipidemia.
T. Aitman (1997)
Regulatory variations in the era of next‐generation sequencing: Implications for clinical molecular diagnostics
Olga Jarinova (2012)
Cellular and Molecular Characterization of the Sterol-Regulatory Element-Binding Protein-1
Philosophisch-Naturwissenschaftlichen Fakultät (2004)
Primary disorders of LDL-cholesterol metabolism
Robert S Rosenson (2011)
Intestinal transcription and synthesis of apolipoprotein AI is regulated by five natural polymorphisms upstream of the apolipoprotein CIII gene.
S. Naganawa (1997)
Functional analysis of four LDLR 5′UTR and promoter variants in patients with familial hypercholesterolaemia
Amna Khamis (2015)
Regulatory mutations in the human lipoprotein lipase gene in patients with familial combined hyperlipidemia and coronary artery disease.
W. Yang (1996)
HindIII DNA polymorphism in the lipoprotein lipase gene and plasma lipid phenotypes and carotid artery atherosclerosis
L. Chen (1996)
No evidence of linkage between familial combined hyperlipidemia and genes encoding lipolytic enzymes in Finnish families.
P. Pajukanta (1997)
Mutations in the promoter region of the androgen receptor gene are not common in males with idiopathic infertility.
F. Ghadessy (1999)
Regulatory variation and human disease
M. T. Maurano (2013)
Evidence of linkage of HDL level variation to APOC3 in two samples with different ascertainment
F. Gagnon (2003)
Genome scan for quantitative trait loci influencing HDL levels: evidence for multilocus inheritance in familial combined hyperlipidemia
F. Gagnon (2005)
Lipoprotein lipase: structure, function, regulation, and role in disease
J. R. Mead (2002)
Identificación de distintos loci de susceptibilidad relacionados al desarrollo de diabetes de inicio temprano y enfermedad cardiovascular en familias mexicanas
S. Canizales-Quinteros (2005)
Linkage of a candidate gene locus to familial combined hyperlipidemia: lecithin:cholesterol acyltransferase on 16q.
B. Aouizerat (1999)
Successful pregnancy outcome in a patient with severe chylomicronemia due to compound heterozygosity for mutant lipoprotein lipase.
K. Al-Shali (2002)
The Mystery of Diabetes and Atherosclerosis: Time for a New Plot
C. Semenkovich (1997)
The familial chylomicronemia syndrome.
S. Santamarina-Fojo (1998)
Targeted sequencing of candidate genes of dyslipidemia in Punjabi Sikhs: Population-specific rare variants in GCKR promote ectopic fat deposition
D. Sanghera (2019)
Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis.
H. Wittrup (1999)
Two novel apolipoprotein A‐IV variants in individuals with familial combined hyperlipidemia and diminished levels of lipoprotein lipase activity
S. Deeb (1996)
Pathogenic classification of LPL gene variants reported to be associated with LPL deficiency.
Rute Rodrigues (2016)
Indinavir inhibits sterol-regulatory element-binding protein-1c-dependent lipoprotein lipase and fatty acid synthase gene activations
A. Miserez (2002)
Diagnostic Pitfalls during Therapy for Extreme Hypertriglyceridaemia
M. Orth (1997)
Genetic dissection of familial combined hyperlipidemia.
P. Eurlings (2001)
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase the binding activity and nuclear level of Oct-1 in mononuclear cells.
M. Ortego (2002)
Lipoprotein lipase and atherosclerosis
J. Kobayashi (1998)
Genomewide scan for familial combined hyperlipidemia genes in finnish families, suggesting multiple susceptibility loci influencing triglyceride, cholesterol, and apolipoprotein B levels.
P. Pajukanta (1999)
Medikamentöse und diätetische Therapie der Hyperlipidämie im Kindesalter: Evaluation von Wirksamkeit, Nebenwirkungen und Compliance im Patientenkollektiv der Kinder-Lipidambulanz von 1997-2000
Sonja Maria Brümmer (2002)
Molecular pathobiology of the human lipoprotein lipase gene.
V. Murthy (1996)
Compound heterozygosity of Leu252Val and Leu252Arg causing lipoprotein lipase deficiency in a Chinese patient with hypertriglyceridemia
Chan (2000)
See more
Semantic Scholar Logo Some data provided by SemanticScholar